Emerging potential of parenteral estrogen as androgen deprivation therapy for prostate cancer - Abstract

Androgen deprivation therapy (ADT) is a key management strategy for prostate cancer (PC), achieved commonly by administration of luteinizing hormone-releasing hormone agonist (LHRHa), ADT markedly suppresses both male and female sex hormones which results in "castration syndrome", a constellation of adverse events such as muscle weakness, impairment of glucose and lipid metabolism, impotence, osteoporosis, and fractures.

Recent evidence suggests that estrogen, in the parenteral form, may emerge as an alternative to LHRHa as it offers potential benefits of arresting PC growth as well as avoiding some of the estrogen deficiency related toxicities of LHRHa by maintaining endogenous levels of estrogen.

Written by:
Ali Shah SI.   Are you the author?
Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London W12 ONN, United Kingdom.

Reference: South Asian J Cancer. 2015 Apr-Jun;4(2):95-7.
doi: 10.4103/2278-330X.155699


PubMed Abstract
PMID: 25992351

UroToday.com Prostate Cancer Section

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe